Decreased serum iron concentration and total iron binding capacity are associated with serious Crohn’s disease

Jingling Su1,2, Yandan Ren1,2, Lupeng Liu1, Yiqun Hu3, Huaxiu Shi1, Jianlin Ren4 & Chenxi Xie1

This study aimed to investigate whether serum indicators related to iron stores in the body are associated with clinical and endoscopic disease severity. Eighty-four patients with Crohn’s disease (CD) and twenty-four healthy volunteers were included. The indicators related to iron stores were detected within one week after endoscopic and CT enterography examinations. Patients were divided into three groups according to the CDAI (Crohn’s disease activity index) scores. Serum iron levels were decreased in all groups \((p < 0.05)\), and the values of remission group were higher than those of moderate group \((p < 0.001)\). The total iron binding capacity (TIBC) values of the moderate group were lower than those of the controls and the other groups \((p < 0.05)\). None of the indicators differed significantly among the patients classified by SES-CD \((p > 0.05)\). Underweight, decreased serum iron and TIBC were independent risk factors for moderate clinical disease. Combined detection of decreased serum iron and TIBC was helpful in differentiating severe patients. The sensitivity and specificity were 32.7% and 100%, respectively \((\text{AUC} = 0.812, p < 0.01)\). Decreases in serum iron and TIBC were associated with the clinical activity of CD. Combined detection of the two indicators was conducive to screening serious disease.

Abbreviations

CD  Crohn’s disease
CDAI  Crohn’s disease activity index
SES-CD  Simple endoscopic score of Crohn’s disease
CTE  CT enterography
DcytB  Duodenal cytochrome B
DMT1  Divalent metal transporter 1
DC  Dendritic cell
SI  Serum iron
TIBC  Total iron binding capacity
Tf  Transferrin
TSAT  Transferrin saturation
BMI  Body mass index

Patients with Crohn’s disease (CD) develop various extraintestinal complications. Iron deficiency can be encountered in 13%-90% of patients according to previous reports\(^1,2\). Iron deficiency plays a key role in affecting the quality of life of CD patients, resulting in symptoms, such as anemia, fatigue, sleep disorders, attention deficits and reduced functional capacity\(^3,4\). Factors leading to iron deficiency include bleeding, reduced iron absorption and immune regulation.

Cytokines, such as IL-6 and TNF-a, can alter serum iron parameters by regulating the expression of hepcidin\(^5,6\). The production of active hepcidin by the liver is increased upon stimulation by cytokines from the inflamed bowel. Hepcidin can bind to the iron exporter ferroportin1 on the basolateral membrane of enterocytes, leading to protein internalization and degradation\(^8,9\), this limits the efflux of iron to the plasma. Overload of iron

---

\(^1\)Department of Gastroenterology, Zhongshan Hospital Xiamen University, Xiamen 361000, Fujian Province, China.
\(^2\)These authors contributed equally: Jingling Su and Yandan Ren.
content in enterocytes reduces the expression of duodenal cytochrome B (DcytB) and divalent metal transporter 1 (DMT1) on the brush border membrane, inhibiting dietary iron absorption. Another important source of hepcidin is dendritic cells (DCs) in the gut. In the absence of DC-derived hepcidin, iron can be released from macrophages and neutrophils to the lumen through ferroportin. Basseri RJ et al. found that serum hepcidin was positively correlated with IL-6 and negatively correlated with hemoglobin in anemia of chronic disease (ACD). This suggested that iron stored in these inflammatory cells is an important source of hematopoiesis in CD patients with ACD.

Although hepcidin is a key mediator of anemia in active CD patients, it is not tested routinely, partially because it may be difficult to distinguish active or inactive forms by commonly used immunoassays. Semrin G et al. measured iron status in young CD patients. They showed that the level of serum iron and the total iron binding capacity were decreased in active CD patients due to impaired oral iron absorption. Therefore, we hypothesized that the indicators related to serum iron parameters may be candidates for evaluating disease severity.

Thus, the aims of the current study are (1) to compare the differences in serum indicators related to iron stores in the body between CD patients and controls and (2) to investigate whether these indicators are associated with disease severity.

Results

Demographic characteristics of the patients. A total of one hundred twenty-nine CD patients who were first admitted to our hospital were screened. Seventeen with a history of intestinal surgery and twenty-eight unable to tolerate endoscopy or CTE examination were excluded from this study. However, four who underwent laparoscopic appendectomy were included. Ultimately, eighty-four patients and twenty-four healthy volunteers were enrolled in the analysis (Table 1).

Comparison of the indicators related to serum iron parameters among patients classified by CDAI scores and controls

The patients were divided into three groups according to the CDAI scores. None with severe activity could be found in our study (Table 2). The serum iron concentration was decreased in all the groups ($p < 0.05$). The values of the moderate group were lower than those of the remission group ($p < 0.001$), but the difference was not significant between the remission and mild groups ($p > 0.05$).

The level of TIBC was decreased significantly in the moderate group compared with controls and the other groups ($p < 0.05$), but the values were similar between controls and the other groups ($p > 0.05$).

The transferrin values of the moderate group were lower than those of the remission group and the controls ($p < 0.05$). The difference was not significant between the other groups and the controls ($p > 0.05$).

Transferrin saturation was lower in the mild and moderate groups than in the controls ($p < 0.05$). However, the values did not differ significantly among the three groups ($p > 0.05$).

There was no significant difference in ferritin values between CD patients and controls ($p > 0.05$).

### Table 1. Demographic data of the patients and controls. BMI: body mass index. For age and BMI: Wilcoxon rank-sum test. For gender distribution: Chi square test.

|                  | CD patients (n = 84) | Controls (n = 24) | p value |
|------------------|---------------------|-------------------|---------|
| Age (years)      | 28 (22,33.75)       | 47 (39.50,51.75)  | 0.00    |
| Male (%)         | 64.29%              | 45.83%            | 0.103   |
| BMI (kg/m²)      | 18.96 (17.14,21.44) | 22.89 (20.90,26.65) | 0.00 |

### Table 2. Comparison of the serum indicators among patients classified by CDAI scores and controls. TIBC: total iron binding capacity. For TIBC: One-way ANOVA. For the other parameters: Kruskal–wallis H test. $p < 0.05$ means that the distribution of values in each group is not equal. The letter a means that the difference is significant when compared to the controls separately. The letter b means that the difference is significant when compared to the moderate group separately.

|                  | Remission (n = 15) | Mild (n = 16) | Moderate (n = 53) | Control (n = 24) | p value |
|------------------|--------------------|--------------|-------------------|------------------|---------|
| Iron (µmol/L)    | 10.50a,b (8.50,14.30) | 7.65a (5.55,10.78) | 5.60a (3.80,9.60) | 16.15 (14.15,22.25) | 0.00    |
| TIBC (µmol/L)    | 53.29 ± 11.58b (56.80,200) | 52.23 ± 13.01b (39.85,187.20) | 43.67 ± 9.34a (47.95,212.75) | 53.58 ± 9.81 (62.32,33) | 0.00    |
| Ferritin (µg/L)  | 124.80 (69.80,200) | 66.60 (39.85,187.20) | 88.10 (47.95,212.75) | 207.65 (62,323.68) | 0.182   |
| Transferrin (g/L)| 2.32a (1.91,2.72) | 2.12 (1.78,2.67) | 1.87a (1.62,2.12) | 2.15 (2.03,2.58) | 0.00    |
| Transferrin saturation (%) | 27 (15,33) | 16a (11,22.25) | 14a (9, 21.75) | 32 (25,44) | 0.00    |
Chronic bleeding caused by segmental ulceration or mucosal inflammation predisposes to lose massive severity and found that the detection of decreased serum iron and total iron binding capacity was effective in screening serious disease. This is consistent with the progression in Crohn’s disease. CD can affect any region within the gastrointestinal tract, often accompanied by complicated extraintestinal manifestations. Iron deficiency (ID) and iron deficiency anemia (IDA) are frequently encountered in up to 90% of IBD patients due to chronic active illness. Oral iron would be ineffective in patients with higher CRP, and is harmful to mucosal healing. Oral iron therapy was associated with decreased abundance of Faecalibacterium prausnitzii and is associated with serum iron deficiency. In addition, the combined use of decreased serum iron and TIBC was effective in distinguishing serious disease, with a sensitivity of 32.7% and a specificity of 100% (AUC = 0.812, p < 0.01).

### Discussion

Crohn's disease is a recurrent disorder of the gastrointestinal tract, often accompanied by complicated extraintestinal manifestations. Iron deficiency (ID) and iron deficiency anemia (IDA) are frequently encountered in up to 90% of IBD patients due to chronic active illness. Oral iron would be ineffective in patients with higher CRP, and is harmful to mucosal healing. Oral iron therapy was associated with decreased abundance of Faecalibacterium prausnitzii, Ruminococcus bromii, Dorea sp. and Collinsella aerofaciens. Reduction in intestinal probiotic community leads to the invasion and colonization of pathogenic bacteria. Intestinal iron accumulation can aggravate inflammation by suppressing Bifidobacterium species, and is associated with serum iron deficiency. In this study, we evaluated the association between serum indicators related to iron stores and disease severity and found that the detection of decreased serum iron and total iron binding capacity was effective in screening serious disease.

In this study, serum iron concentration and TIBC were decreased significantly in moderate clinical disease. This is consistent with the progression in Crohn’s disease. CD can affect any region within the gastrointestinal tract. Chronic bleeding caused by segmental ulceration or mucosal inflammation predisposes to lose massive

### Table 3. Comparison of the serum indicators among patients classified by SES-CD and controls. TIBC: total iron binding capacity. For TIBC: One-way ANOVA. For the other parameters: Kruskal–Wallis H test. p < 0.05 means that the distribution of values in each group is not equal. The letter a means that the difference is significant when compared to the controls separately.

| Indicator                  | Remission (n = 13) | Mild (n = 17) | Moderate (n = 34) | Severe (n = 20) | Control (n = 24) | p value |
|----------------------------|-------------------|--------------|-----------------|---------------|-----------------|---------|
| Iron (µmol/L)              | 8.8* (6.40, 11.75)| 7.69* (5.65, 10.70)| 8.25* (4.65, 11.85)| 4.70* (3.75, 8.20) | 16.15 (14.35, 22.25) | 0.000   |
| TIBC (µmol/L)              | 48.88 ± 12.98     | 48.73 ± 11.96 | 46.66 ± 10.76   | 45.22 ± 11.06 | 53.58 ± 9.81    | 0.119   |
| Ferritin (ug/L)            | 65.90 (31.95, 154.00) | 124.80 (39.30, 204.00) | 126.35 (60,20,211.90) | 68.90 (40,63,186.30) | 207.65 (62,33,268.90) | 0.147   |
| Transferrin (g/L)          | 1.95 (1.67, 2.44) | 2.12 (1.65, 2.58) | 1.98 (1.68, 2.31) | 1.86 (1.65, 2.52) | 2.15 (2.03, 2.50) | 0.049   |
| Transferrin saturation (%) | 21* (10, 29.5)    | 17.50* (11.75, 31.50) | 17.50* (9.50, 26) | 11.50* (9.16, 75) | 32 (27.44)     | 0.000   |

Comparison of the indicators related to serum iron parameters among patients classified by SES-CD and controls. The patients were divided into four groups according to the SES-CD. The results of these comparisons were shown in Table 3. The values of serum iron and transferrin saturation were lower in all the groups than in the controls. However, the values did not differ significantly among the four groups. Although there was a decreasing trend of transferrin values in all the groups, the differences were not significant when compared with controls separately. There were no significant differences in ferritin and TIBC values between CD patients and controls. The results suggested that there was no correlation between these indicators and lesion severity under endoscopy.

Association of the indicators related to serum iron parameters with clinical disease severity. We found that serum iron, TIBC and transferrin were significantly decreased in patients with moderate clinical disease, but the differences were not significant between the mild and remission groups. These results suggested that these indicators may be candidates for evaluating disease severity.

The cutoff value of serum iron used to distinguish moderate from mild/remission groups was 5.25 µmol/L (AUC = 0.729, p = 0.001), the sensitivity was 48.1%, and the specificity was 93.3%.

The cutoff value of TIBC used to distinguish moderate from mild/remission groups was 47.25 µmol/L (AUC = 0.737, p = 0.002), the sensitivity was 73.1%, and the specificity was 67.7%.

The cutoff value of transferrin used to distinguish moderate from mild/remission groups was 2.07 g/L (AUC = 0.708, p = 0.003), the sensitivity was 75%, and the specificity was 64.5%.

The three cutoff values above were used to divide all the CD patients into two groups separately. Patients were classified by age, disease location or behavior according to the Montreal classification. A body mass index (BMI) < 18.5 kg/m² was used as the demarcation of underweight. Hemoglobin values of < 130 g/L for males and < 120 g/L for females were used as the demarcations of anemia. The comparison results of these metrics between two groups were shown in Table 4.

Logistic regression analysis was applied to identify the potential risk factors for serious Crohn's disease. The results showed that underweight, decreased serum iron and TIBC were independent risk factors for serious disease (for underweight, OR = 7.34, 95% CI 1.85–28.87, for decreased serum iron, OR = 21.31, 95% CI 3.52–128.88, for decreased TIBC OR = 8.259, 95% CI 2.267–30.08).

We found that serum iron and TIBC correlated negatively with CDAI scores (r = − 0.513, r = − 0.409, both p < 0.05).

In addition, the combined use of decreased serum iron and TIBC was effective in distinguishing serious disease, with a sensitivity of 32.7% and a specificity of 100% (AUC = 0.812, p < 0.01).
amounts of iron\textsuperscript{3,4}. The involvement of the duodenum-jejunum and reduced daily food intake due to fear of gastrointestinal symptoms can aggravate iron malnutrition\textsuperscript{4}. Furthermore, the complex interplay of cytokines produced by the inflamed intestine and the surrounding mesentery and hepcidin can also contribute to iron deficiency\textsuperscript{1,20}. Two major relevant sources of hepcidin are hepatocytes and dendritic cells in the intestinal tract\textsuperscript{10,17}. Functionally active hepcidin from the liver is upregulated by cytokines and binds to ferroportin on enterocytes via the blood circulation, inducing degradation of this iron transporter\textsuperscript{9}. In the absence of DC-derived hepcidin during inflammation, ferroportin in macrophages and neutrophils is retained, and iron is released extracellularly\textsuperscript{10}. These changes limit iron absorption and transport to the plasma. Systemic inflammation had a significant impact on serum iron homeostasis. This was in line with our results showing that serum iron and TIBC correlated negatively with CDAI scores, and the specificity of decreased serum iron was very high in distinguishing moderate CD. Combined detection of these two indicators would be useful in screening serious CD.

Ferritin is a measure of stored iron content and is decreased in the condition of iron deficiency\textsuperscript{21}. Previous studies reported that ferritin was positively correlated with hepcidin and negatively correlated with the efficacy of oral iron treatment\textsuperscript{5,22}. These results suggested that ferritin may be increased due to active intestinal inflammation\textsuperscript{23}. For CD, severe inflammation is often accompanied by iron deficiency, and false normal ferritin may be found\textsuperscript{4}. This may explain why the difference in ferritin was not significant between patients and controls in our study. Both serum ferritin and transferrin are active-phase reactants\textsuperscript{9}. Transferrin is responsible for transferring iron from the sites of absorption to all tissues. The level is high in patients with iron deficiency, but it will decrease during inflammation\textsuperscript{9}. Therefore, false normal values were commonly found in the condition of anemia of inflammation. In our study, although transferrin and transferrin saturation seemed lower in moderate CD, neither of them was useful in screening serious disease.

We found that disease localization and behavior were not associated with severity. This was consistent with the study of Aksan A et al\textsuperscript{5}. It seemed that serum iron concentration and transferrin saturation tended to decrease in patients with higher SES-CD, but the differences were not significant. This result was reasonable because SES-CD is based on colonoscopy findings and cannot reflect lesions beyond the stricture or in the upper gastrointestinal tract\textsuperscript{24}. Although ulcers are an important indicator of SES-CD, iron deficiency is not only associated with ulceration or bleeding\textsuperscript{4,13,25,26}.

Dietary Fe intake is reduced in CD patients as a result of avoidance of certain fiber-rich and Fe-fortified cereals due to the fear of exacerbating gastrointestinal symptoms\textsuperscript{4}. Active disease can decrease absorption and increase energy expenditure\textsuperscript{27,28}. Combined, these factors contribute to the weight loss observed. Undernutrition has a negative impact on the disease process and increases the rate of postoperative complications and mortality\textsuperscript{29–31}.

### Table 4. Comparison of metrics between CD patients with different disease severities. BMI: body mass index. UGIT: upper gastrointestinal tract. TIBC: total iron binding capacity. For age, BMI, iron, TIBC and transferrin: rank-sum test. For gender distribution, location, behavior and anemia: Chi square test. For transferrin saturation and ferritin: wilcoxon rank-sum test. Only the parameters with statistical differences between groups were included in the regression analysis.

|                      | Mild/Remission (n = 31) | Moderate (n = 53) | p value |
|----------------------|-------------------------|-------------------|---------|
| Age (years)          |                         |                   |         |
| ≤ 16 (n)             | 7                       | 4                 | 0.037   |
| 17–40 (n)            | 22                      | 41                |         |
| > 40 (n)             | 2                       | 8                 |         |
| Male (n)             | 21                      | 33                | 0.613   |
| BMI (< 18.5 kg/m\textsuperscript{2}) | 5                   | 31                 | 0.00    |
| Location (n)         |                         |                   |         |
| Ileal                | 4                       | 3                 | 0.680   |
| Colonic              | 2                       | 4                 |         |
| Ileocolonic          | 18                      | 31                |         |
| UGIT involved        | 7                       | 15                |         |
| Behavior (n)         |                         |                   | 0.116   |
| Non-stricturing, non-penetrating | 12                 | 14                |         |
| Structuring          | 12                      | 22                |         |
| Penetrating          | 5                       | 4                 |         |
| Stricturing and penetrating | 2              | 13                |         |
| With anemia (n)      | 16                      | 46                | 0.00    |
| Iron (< 5.25 µmol/L) (n) | 2                   | 26                |         |
| TIBC (< 47.25 µmol/L) (n) | 10                 | 39                |         |
| Transferrin (< 2.07 g/L) (n) | 11                | 39                | 0.001   |
| Transferrin saturation(%) | 18 (14,28)             | 14 (9,21.75)       | 0.042   |
| Ferritin (µg/L)      | 114.80 (49,196)         | 88.10 (47.95,212.75) | 0.774   |
instruments by an investigator blinded to the case–control status. All assays were performed according to the instructions of relevant analyzer. Ferritin was detected by Roche Cobas e602 Automatic immune analyzer. Transferrin and TSAT% were assessed in the study. These indicators are commonly used in clinical practice and are easy to detect. 2 ml blood samples should be stored at 2–8 °C. Serum iron and TIBC were detected by Beckmann AU5800 biochemical analyzer. Biopsies should not be taken from the bottom of ulcer. The findings were recorded according to the simple endoscopic score of Crohn's disease (SES-CD). Four endoscopic variables were scored from 0 to 3: size of ulcers (0 = none; ulcer diameter 0.1–0.5 cm = 1; 0.5–2 cm = 2; > 2 cm = 3); ulcerated surface (0 = none; < 10% = 1; 10%–30% = 2; > 30% = 3); surface affected by any lesions (0 = none; < 50% = 1; 50–75% = 2; > 75% = 3); and presence of narrowing (0 = none; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). SES-CD is the sum of these scores in the five segments (terminal ileum, right colon, transverse colon, left colon and rectum). In this study, SES-CD scores between 0 and 2 suggested remission, 3–6 mild activity, 7–15 moderate activity and ≥ 16 severe activity31.

Assessment of indicators related to serum iron homeostasis. Five indicators, including serum iron (SI), total iron binding capacity (TIBC), ferritin, transferrin (TT), and transferrin saturation (TSAT%), were assessed in the study. These indicators are commonly used in clinical practice and are easy to detect. 2 ml blood samples were taken after fasting for at least 8 h. The serum and blood cells shall be separated within 2 h after collection, and the detection shall be completed within 8 h. If the process could not be completed in time, the serum samples should be stored at 2–8 °C. Serum iron and TIBC were detected by Beckmann AU5800 biochemical analyzer. Ferritin was detected by Roche Cobas e602 Automatic immune analyzer. Transferrin and TSAT% were detected by BN II specific protein analyzer. All assays were performed according to the instructions of relevant instruments by an investigator blinded to the case–control status.

Statistical analysis. Data are expressed as either the mean ± SD or the median (interquartile range). One-way ANOVA was used to compare differences if the values for a metric followed normal distribution; otherwise, the rank-sum test was used. The Spearman rank correlation coefficient was used to analyze the correlation between CDAI scores and the levels of serum iron or total iron binding capacity. Logistic regression analysis was applied to investigate the association of serum indicators with clinical disease severity. A p value less than 0.05 was considered statistically significant. The statistical analysis was accomplished using SPSS20.0 (SPSS Inc., Chicago, IL, USA).

Conclusion In summary, our findings suggested that decreased serum iron and total iron binding capacity were associated with the severity of Crohn's disease. Decreased serum iron was less sensitive than TIBC in distinguishing moderate CD from the mild/remission group but showed higher specificity. The combined use of these two indicators for screening serious disease would be helpful in developing targeted treatment programs.

Materials and Methods Subjects. Consecutive patients diagnosed with Crohn's disease (CD) in our hospital from February 2018 to November 2020 were enrolled in the prospective study. Patients were excluded if they had the following conditions: unable to undergo colonoscopy and CT enterography (CTE) examinations due to severe intestinal obstruction or perforation; gastrointestinal tumors; previous abdominal surgery (except laparoscopic appendectomy); other systemic diseases that can lead to anemia; received oral/intravenous iron treatment or blood transfusion within 3 months prior to the study; women in the pregnancy or breast-feeding stage; and severe renal, cardiac or pulmonary disease. Ultimately, eighty-four were included. Colonoscopy and CTE were performed for all within 1 week before blood samples were taken. Another 24 volunteers with normal mucosa via colonoscopy and without gastrointestinal symptoms, systemic disorders or major abdominal surgery were simultaneously recruited as healthy controls.

The study protocol and the recruitment of the patients and controls were approved by the Ethics Committee of Zhongshan Hospital Xiamen University (Ethical approval No: xmzsyyky 2021–166). Written informed consent was obtained from all individuals before starting any study procedure. We confirmed that all methods were performed in accordance with the relevant guidelines and regulations.
Ethics approval and consent to participate. The study protocol and the recruitment of the patients and controls were approved by the Ethics Committee of Zhongshan Hospital Xiamen University. Approval No: xmszyky 2021–166. Written informed consent was obtained from all individuals before starting any study procedure.

Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 24 October 2021; Accepted: 14 February 2022
Published online: 10 March 2022

References
1. Kulnigg, S. & Gasche, C. Systematic review: managing anaemia in Crohn’s disease. Aliment Pharmacol. Ther. 24(11–12), 1507–1523 (2006).
2. Peyrin-Biroulet, L., Williet, N. & Caboc, P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am. J. Clin. Nutr. 102(6), 1585–1594 (2015).
3. Murawska, N., Fabisiak, A. & Fichna, J. Anemia of chronic disease and iron deficiency anemia in inflammatory bowel diseases: pathophysiology, diagnosis, and treatment. Inflamm. Bowel Dis. 22(5), 1198–1208 (2016).
4. Bou-Fakhredin, R., Halawi, R., Roumi, J. & Taher, A. Insights into the diagnosis and management of iron deficiency in inflammatory bowel disease. Expert Rev. Hematol. 10, 801–808 (2017).
5. Aksan, A., Wohlrath, M., Iqbal, T. & Dignass, A. & Stein, J. Inflammation, but not the underlying disease or its location, predicts oral iron absorption capacity in patients with inflammatory bowel disease. J. Crohns Colitis 14, 316–322 (2020).
6. Nemeth, E. et al. IL-6 mediates hypoferrinaemia of inflammation by inducing the synthesis of the ironregulatory hormone hepcidin. J. Clin. Invest. 113, 1271–1276 (2004).
7. Song, S. N. et al. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res. Ther. 15, R141 (2013).
8. Semrin, G. et al. Impaired intestinal iron absorption in Crohn’s disease correlates with disease activity and markers of inflammation. Inflamm. Bowel Dis. 12, 1101–1106 (2006).
9. Kaitha, S., Bashir, M. & Ali, T. Iron deficiency anemia in inflammatory bowel disease. World J. Gastrointest. Pathophysiol. 6, 62–72 (2015).
10. Bessman, N. J. et al. Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote mucosal healing. Science 368, 186–189 (2020).
11. Basseri, R. J. et al. Hepcidin is a key mediator of anemia of inflammation in Crohn’s disease. J. Crohns Colitis 7, e286–e291 (2013).
12. Macougall, I. C., Malyaszko, J., Hider, R. C. & Bansal, S. S. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 5, 1681–1689 (2010).
13. Satsangi, J., Silverberg, M. S., Vermeire, S. & Colombel, J. F. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut 55, 749–753 (2006).
14. Mentella, M. C., Scaldaferrari, F., Pizzoferrato, M., Gabarrini, A. & Miggiano, G. The association of disease activity, BMI and phase angle with vitamin D deficiency in patients with IBD. Nutrients 11, 2583 (2019).
15. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity (WHO, 2011).
16. Goldberg, N. D. Iron deficiency anemia in patients with inflammatory bowel disease. Clin. Exp. Gastroenterol. 6, 61–70 (2013).
17. Iqbal, T. et al. Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia. Dig. Dis. Sci. 60(5), 1375–1381 (2015).
18. Sarkar, A. & Mandal, S. Bifidobacteria-Insight into clinical outcomes and mechanisms of its probiotic action. Microbiol. Res. 192, 159–171 (2016).
19. Lee, T. et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut 66, 863–871 (2017).
20. Strong, S. A., Pizarro, T. T., Klein, J. S., Cominelli, F. & Fiocchi, C. Proinflammatory cytokines differentially modulate their own expression in human intestinal mesenchymal cells. Gastroenterology 114, 1244–1256 (1998).
21. Stein, J. & Dignass, A. U. Management of iron deficiency anemia in inflammatory bowel disease: a practical approach. Ann. Gastroenterol. 26, 104–113 (2013).
22. Mecklenburg, I. et al. Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease. J. Crohns Colitis 8, 1392–1397 (2014).
23. Gomollón, F. & Gisbert, J. P. Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide. Drugs 73, 1761–1770 (2013).
24. Khanna, R. et al. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn’s disease: Recommendations for clinical trial design. Inflamm. Bowel Dis. 20, 1850–1861 (2014).
25. Dallalio, G., Law, E. & Means, R. T. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 107, 2702–2704 (2006).
26. Dieleman, L. A. & Heizer, W. D. Nutritional issues in inflammatory bowel disease. Gastroenterol. Clin. North Am. 27, 435–445 (1998).
27. Capristo, E., Addolorato, G., Mingrone, G., Greco, A. V. & Gabarrini, G. Effect of disease localization on the anthropometric and metabolic features of Crohn’s disease. Am. J. Gastroenterol. 93, 2411–2419 (1998).
28. Bischoff, S. C. et al. ESPEN’s practical guideline: clinical Nutrition in inflammatory bowel disease. Clin. Nutr. 39, 632–653 (2020).
29. Kupperling, D. et al. Nutritional screening for risk prediction in patients scheduled for abdominal operations. Br J Surg 99, 728–737 (2012).
30. Heyland, D. K. et al. Total parental nutrition in the surgical patient: a meta-analysis. Can J. Surg. 44, 102–111 (2001).
31. Lewis, S. J., Andersen, H. K. & Thomas, S. Early enteral nutrition within 24 h of intestinal surgery versus later commencement of feeding: a systematic review and meta-analysis. J. Gastrointest. Surg. 13, 569–575 (2009).
32. Sandborn, W. J. et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 122, 512–530 (2002).
33. Lichtenstein, G. R. et al. ACG clinical guideline: Management of Crohn’s disease in adults. Am. J. Gastroenterology 113, 481–517 (2018).
Author contributions
Study concept, acquisition of data, analysis, drafting: J.S. and Y.R.; acquisition of data and analysis: L.L., Y.H., H.S. and J.R.; study concept, acquisition of data, analysis, drafting, study supervision, and finalizing the manuscript: C.X.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to C.X.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022